Tranzyme Pharma to Present Ulimorelin Data Showing Reduction in Daily Vomiting in Patients with Diabetic Gastroparesis
Oral Presentation at 2010 Joint International Meeting in Neurogastroenterology and Motility (NGM), Boston MA August 26-29
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Aug 25, 2010 - Tranzyme Pharma announced today that John Wo, MD, Professor of Medicine, Director, Clinical Research, Division of Gastroenterology, Hepatology and Nutrition, University of Louisville, Louisville, KY, will present ulimorelin Phase 2 data at this year's Joint International NGM Meeting on Saturday, August 28, 2010. The conference is being held at the Westin Copley Place in Boston, MA. Professor Wo is scheduled to speak at 11:00am during Oral Session 3.
The presentation entitled, “Ulimorelin (ghrelin agonist) effects on daily vomiting due to diabetic gastroparesis” will summarize the effects of ulimorelin in subjects with daily, moderate to severe vomiting.
Gastroparesis, in severe cases, can be responsible for frequent hospitalizations and emergency room admissions due to recurrent nausea and vomiting, which may be associated with dehydration, malnutrition and weight loss due to inadequate caloric food intake. Currently, there are no safe and effective treatments for gastroparesis. Earlier prescription medications used to treat this condition were either withdrawn from the market or must carry a “black box” warning due to serious side effects.
In Tranzyme's Phase 2 study of diabetic patients with advanced gastroparesis, ulimorelin, given intravenously once daily for four days, demonstrated clinically and statistically significant improvements in multiple gastroparesis-related symptoms, including vomiting and nausea.
Patients who had moderate to severe daily vomiting during the 4 day run-in period (just prior to the study start), reported a marked reduction in the number of days with vomiting during the subsequent 4-day treatment period.
About Tranzyme Pharma
Tranzyme Pharma is a clinical-stage drug development company that discovers and develops novel small molecule macrocyclic drugs for both acute care (hospital-based) and chronic indications with significant unmet medical needs. The Company's pipeline is derived from its proprietary drug discovery (chemistry) technology, MATCH™, and targets products for gastrointestinal motility, metabolic diseases and cancer supportive care.
Tranzyme has two corporate partnerships -- a broad drug discovery partnership with Bristol-Myers Squibb to discover, develop and commercialize novel drug candidates in multiple therapeutic areas, and a recently announced European licensing agreement with Norgine for the co-development of Tranzyme's intravenous ghrelin agonist, ulimorelin. www.tranzyme.com.
Contact: Tranzyme Pharma
Vipin K. Garg, PhD, 919-313-4764
President and CEO
Jennifer A. Filbey, PhD, 256-417-8568
VP, Business Development
Susan S. Josselyn, 919-313-4761
Corporate Communications Manager
Posted: August 2010